Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period.
about
Current and emerging azole antifungal agentsClinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditionsClinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitroToxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal MeningitisIn vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
P2860
Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Amphotericin B as primary ther ...... ver a relatively short period.
@en
Amphotericin B as primary ther ...... ver a relatively short period.
@nl
type
label
Amphotericin B as primary ther ...... ver a relatively short period.
@en
Amphotericin B as primary ther ...... ver a relatively short period.
@nl
prefLabel
Amphotericin B as primary ther ...... ver a relatively short period.
@en
Amphotericin B as primary ther ...... ver a relatively short period.
@nl
P2093
P1476
Amphotericin B as primary ther ...... ver a relatively short period.
@en
P2093
Franzetti M
Pellizzer G
de Lalla F
P304
P407
P577
1995-02-01T00:00:00Z